Search results
Found 10672 matches for
Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.
Study with Us
The Department of Oncology has an established, world-leading graduate training programme.
Scientific Research Facilities
The Department’s world-leading scientific research and specialist facilities provide essential support, expertise and knowledge to our research programmes. They afford the added value of partnership and expert advice in developing experiments, designing equipment, maintaining cutting edge technology and providing clinical support. We have invested heavily in these facilities to underpin the expanding Department and plug the gaps in support for our key areas of focus in cancer research. We also have strong links with other parts of the University and also tap into local expertise in neighbouring University facilities such as the Target Discovery Institute.